PDF
(Download)
|
- Fenugreek (Trigonella foenum-graecum, Fabaceae)
- Menopause
- FenuSMART™
|
Date:
11-15-2016 | HC# 101651-556
|
Re: Proprietary Fenugreek Extract Alleviates Postmenopausal Symptoms and Increases Estradiol Levels
Shamshad
Begum S, Jayalakshmi HK, Vidyavathi HG, et al. A novel extract of fenugreek
husk (FenuSMART™) alleviates postmenopausal symptoms and helps to establish the
hormonal balance: A randomized, double-blind, placebo-controlled study. Phytother Res. July 13, 2016; [epub
ahead of print]. doi: 10.1002/ptr.5680.
The
physiological, psychological, and sociocultural discomforts associated with
menopause are attributed to a decrease in estrogen levels. Phytoestrogens from
plants may help alleviate menopausal symptoms. The seeds of fenugreek (Trigonella foenum-graecum, Fabaceae) are
used as a culinary spice and are generally recognized as safe (GRAS) by the US
Food and Drug Administration. Fenugreek seeds are a rich source of
phytoestrogens and clinical trials have found that fenugreek seed extract
reduced the severity of menopausal symptoms. The purpose of this randomized,
double-blind, placebo-controlled study was to evaluate the safety and efficacy
of a proprietary fenugreek seed husk extract for the treatment of postmenopausal
symptoms.
Purposive sampling was used to select natural menopausal female patients (n = 130), aged between 45 and 58 years, for this study conducted at M/S Sri Jayadeva
Institute of Cardiovascular Sciences and Research; Bangalore, India. Included
patients did not have menses for ≥ 12 months, had their last menses ≤ 3 years
previously, had moderate to severe postmenopausal discomforts as assessed by a
score of ≥ 25 on the Greene Climacteric Scale (GCS), and had ≥ 3 hot
flashes/day during the last 3-5 weeks. Excluded patients used hormone
replacement therapy previously, had a family history of breast cancer, had a personal
history of malignant neoplasm, were hospitalized during the previous 3 months,
had any cardiac risk factors, or were taking any medication or dietary
supplement.
A total of 88 women
gave informed consent and were randomly assigned to receive either placebo (cellulose)
or fenugreek (FenuSMART™; M/S Akay Flavours & Aromatics Pvt. Ltd.; Cochin, India)
at 500 mg/day for 1 week, and then 1000 mg/day for another 12 weeks. The fenugreek
product was a proprietary hydroethanolic
extract of fenugreek seed husks (FHE) rich in protodioscin, trigonelline, and
4-hydroxyisoleucine. The FHE had a "drug extract ratio of 18:1 (w/w [per
weight]) with respect to fenugreek husks (1 kg FHE was equivalent to 24 kg of
dried fenugreek seeds) … ." The FHE was characterized by a high-performance
liquid chromatography fingerprint profile and met the quality requirement of
the US Pharmacopeia.
At baseline, day 45,
and day 90 (study end), quality of life was assessed with the Short Form-36
(SF-36) Health Survey, and the severity of postmenopausal symptoms was
evaluated with the GCS. Anthropometric data were collected, blood pressure was
measured, and blood was drawn at baseline and study end. The blood samples were
analyzed to determine total cholesterol, triglycerides, high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, very-low-density
lipoprotein cholesterol, estradiol, and calcium levels.
At baseline, there
were no significant differences between groups in terms of demographic
variables, laboratory parameters, or GCS scores. The dropout rate was 27.3% in
the placebo group and 13.6% in the treatment group, "mainly because of their difficulty to appear for follow-ups and strictly
adhere to the conditions of the treatment regime." None of the dropouts were
due to adverse events or intolerance of the FHE. Treatment compliance (measured
by pill counts) was > 95% for both groups.
The FHE group had a
significant improvement in GCS total score compared with baseline (P <
0.001) and placebo (P < 0.001). Scores for the 4 GCS domains (psychological,
vasomotor, physical, and libido) also were significantly lower in the FHE group
compared with the placebo group (P < 0.001 for all). The greatest reductions
were observed in the scores for insomnia (decreased 75%), mood swings (68%), irritability
(65%), night sweats (57%), headache (54%), and hot flashes (47.8%). Approximately
32% of the FHE group reported no hot flashes at study end. Based on SF-36
scores, 73% of the FHE group had a significant improvement in quality of life
compared with placebo (P < 0.001). Compared to baseline, the FHE group had significant
improvements in physical/mental fatigue, enhanced interest in daily work, general
well-being, and mental health (P < 0.05 for all), while a similar increase
was not observed for the placebo group.
Plasma
estradiol increased 120% in the FHE group compared with < 5% in the placebo
group (P < 0.01). Patients who had high levels of estradiol at baseline had
relatively lower increases in estradiol over the course of the study and vice
versa (i.e., those with the lowest baseline levels experienced the greatest
increase in estradiol). Calcium increased 2% in the FHE group compared to a decrease
of 0.8% in the placebo group (P < 0.01). Patients in the FHE group with hypercholesterolemia
at baseline had significant decreases in total cholesterol, LDL, and
triglyceride levels (P < 0.05 for all), while those with a normal lipid
profile at baseline maintained healthy cholesterol levels with no decrease in
HDL. There were no significant changes in anthropometric measures, although
there was a trend towards improvement in body weight (P < 0.06) and hip
circumference (P < 0.08). No adverse events were reported.
In summary, supplementation
with FenuSMART for 90 days significantly alleviated symptoms of menopause,
improved quality of life, and increased serum levels of estradiol in
postmenopausal women. The FHE also had beneficial effects on lipid profiles and
serum calcium levels, and did not cause any adverse reactions. The authors
conclude that FHE is a safe and effective treatment for the management of
postmenopausal symptoms. This study was well designed and reported. Acknowledged
limitations of the study include the purposive
sampling procedure, small sample size, absence of endometrial surveillance, and
lack of measurements of other key hormones (androgens and estrogens), bone
density, and bone calcium levels. Financial support for the study was provided
by M/S Akay Flavours & Aromatics Pvt. Ltd., the manufacturer of FenuSMART;
4 of the authors (Gopakumar, Abin, Balu, and Krishnakumar) are employed by the
company.
—Heather S. Oliff,
PhD
|